- Policy
- Benefit redemption of α-GPC will be promoted soon
- by Lee, Hye-Kyung Dec 7, 2020 06:06am
- As the clinical re-evaluation of Choline alfoscerate is imminent, the NHIS' benefit redemption contract is expected to be pursued sooner or later. The consortium of Daewoong and Chong Kun Dang On the 1st of the month, an online briefing session for clinical reevaluation was held, and it was announced that it would recruit pharmaceutical co
- Policy
- SB16 has been approved for phase III clinical trial
- by Lee, Tak-Sun Dec 7, 2020 06:06am
- Samsung Bioepis is the first in Korea to enter Phase III clinical trial of Prolia's biosimilar, an osteoporosis treatment. The MFDS approved the Phase III clinical trial protocol for a biosimilar candidate for Prolia, SB16, which Samsung Bioepis applied on the 1st. Prolia developed by Amgen was approved in Korea in September 2014. It is
- Policy
- HIRA completes selective reimbursement listing
- by Lee, Hye-Kyung Dec 4, 2020 05:54am
- To reinforce the National Health Insurance (NHI) coverage, the South Korean health authority granted selective reimbursement on 16 out of 23 anticancer therapies without the healthcare reimbursement standard or left as a non-reimbursement with 100-percent copayment rate. According to the list of anticancer treatments with selective reimburse
- Policy
- Life expectancy regulations for RSA drugs will be maintained
- by Lee, Jeong-Hwan Dec 3, 2020 06:01am
- The MOHW has announced that it will not change the two-year life expectancy rule applied to the 'risk sharing system (RSA)' applied to high-priced new drugs such as the latest anticancer drugs and rare disease treatment drugs. This regulation was established by referring to similar overseas systems such as the UK and Australia, and it is b
- Policy
- 16 new drugs listed including Kisqali, Verzenio & Ibrance
- by Kim, Jung-Ju Dec 3, 2020 06:00am
- A total of 16 major new drugs for which insurance benefit coverage was initiated this year were counted. A total of 4 drugs have lowered the burden on patients due to lower benefit standards. Regardless of the estimated size of insurance finance, the tendency to expand flexible coverage was established according to social importance and patient
- Policy
- 3 reimbursed Spinraza use applications from Oct. all cleared
- by Lee, Hye-Kyung Dec 2, 2020 06:05am
- The South Korean health authority has approved of all three cases submitted preliminary approval applications from last month seeking to use spinal muscular atropy (SMA) treatment Spinraza with coverage. Four months after a reimbursement approval, the drug user has to submit an administration monitoring reports for approval on maintenance dos
- Policy
- 3 month-lasting birth control injection withdraws from Korea
- by Lee, Tak-Sun Dec 1, 2020 06:19am
- Pfizer’s contraceptive injection Sayana (medroxyprogesterone acetate) initially received the public’s limelight for the convenience of injecting once every three months, but it has decided to withdraw from the South Korean market. The injection even extended the post-marketing surveillance (PMS) period and showed its commitment to st
- Policy
- NSCLC treatment Vizimpro 30 mg KRW 25,684 per tablet
- by Kim, Jung-Ju Dec 1, 2020 06:15am
- From December, Pfizer Pharmaceutical Korea’s non-small cell lung cancer (NSCLC) treatment Vizimpro (dacomitinib) 30 mg tablet would be priced at 25,684 won with the healthcare reimbursement. The insured pricing for Amgen Korea’s osteoporosis treatment Evenity (romososumab) injection prefilled syringe was set at 123,700 won. South Korea’s
- Policy
- Reimbursement procedure for RSA drugs has been disclosed
- by Lee, Hye-Kyung Nov 30, 2020 06:21am
- The amount of risk-sharing refunds paid to patients by The NHIS for the last five years under the Risk Sharing Agreement (RSA) contract reached &8361;5.46 billion. More than half of them, or &8361;3 billion, were paid out from January to September of this year. Nam-seon Choi, head of the NHIS drug price negotiation department, recently r
- Policy
- NA urges for more COVID-19 vaccine, MOHW to take a survey
- by Lee, Jeong-Hwan Nov 27, 2020 06:29am
- The National Assembly Health and Welfare Committee pressured the Ministry of Health and Welfare (MOHW) and the Ministry of Food and Drug Safety (MFDS) to focus their capacity to seek access to investigational COVID-19 vaccines around the world. Also they ordered the South Korean government to extinguish the people’s concerns about the
